It has also announced the appointment of the company’s new general manager, Craig Bowen. Neuraxpharm Group has announced the launch of its first products in the United Kingdom, as well as the ...
BARCELONA, Spain and DÜSSELDORF, Germany, Nov. 14, 2024 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous ...
Provigil® (modafinil) and Nuvigil® (armodafinil), two of the most trusted and widely prescribed brands in the narcolepsy category, will increase Neuraxpharm's global CNS presence and support market ...
Eight months after Briumvi’s initial green light in the U.S., TG Therapeutics is preparing to debut its multiple sclerosis antibody on the world stage. In a deal unveiled Tuesday, European specialty ...
Neuraxpharm, a portfolio company of Permira, has acquired Medinutrix, a privately-owned specialty pharmaceutical distribution company. Covering approximately 85 percent of the European CNS [central ...
To reduce product lead times, improve orchestration between CMOs, 3PLs, and customers, and avoid lost sales and increased warehouse costs, Neuraxpharm required a more agile, transparent, and scalable ...
LANGENFELD, Germany, July 31, 2019 /PRNewswire/ -- Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces ...
CNS specialist continues growth strategy outside Europe to commercialise CNS treatments, including Nuvigil ® (armodafinil), Modavigil ® (modafinil), and bring BRIUMVI ® (ublituximab) to patients in ...
Europe's leading central nervous system specialty company strengthens its management team in Ireland and reinforces its growth strategy DUSSELDORF, Germany and BARCELONA, Spain, March 15, 2022 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback